Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28653996 | 0.98 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3CA12CA1 | |
| Oxalic Acid SCHEMBL10848188 | 0.89 | CHRNB2 (0.48) | SLC6A4SLC6A2SLC6A3CA1CA2 | |
| SCHEMBL31142632 | 0.84 | CHRNB2 (0.53) | HTR2CHTR2BTDP1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL31142619 | 0.83 | CHRNB2 (0.51) | HTR2CHTR2BTDP1CHRNB2CHRNA4 | |
| SCHEMBL1742193 | 0.83 | SLC6A2 (0.53) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL10804697 | 0.83 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL17542151 | 0.82 | RAB9A (0.65) | MAPTSMN1; SMN2 | |
| SCHEMBL3153942 | 0.81 | CHRNB2 (0.55) | CHRNB2CHRNA4MAOA | |
| SCHEMBL1923468 | 0.80 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL2582519 | 0.80 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054955-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2008059214-A1 | BISAMLDE DERIVATIVES AND USE THEREOF AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| EP-0131435-B1 | PROCESS FOR PREPARING 3-PHENOXY-1-AZETIDINES AND CARBOXAMIDE DERIVATIVES | A.H. ROBINS COMPANY, INCORPORATED (US) | 1987-10-07 | — | — | EP | disclosed |
| EP-0102740-B1 | N-FORMYL AND N-HYDROXYMETHYL-3-PHENOXY-1-AZETIDINECARBOXAMIDES AND THEIR PREPARATION AND USE | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-11-05 | — | — | EP | disclosed |
| EP-0102194-B1 | 3-PHENOXY-1-AZETIDINECARBOXAMIDES AND THEIR USE AND PREPARATION | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-10-22 | — | — | EP | disclosed |
| US-4594189-A | Process for preparing 3-phenoxy-1-azetidines and carboxamide derivatives | A. H. ROBINS COMPANY, INC. (US) | 1986-06-10 | — | — | US | disclosed |
| US-4571393-A | ANTICONVULSANT TREATMENT FOR MAMMALS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-02-18 | — | — | US | disclosed |
| US-4505907-A | ANTICONVULSANTS | A. H. ROBINS COMPANY, INC. (US) | 1985-03-19 | — | — | US | disclosed |
| EP-0131435-A1 | Process for preparing 3-phenoxy-1-azetidines and carboxamide derivatives | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-01-16 | — | — | EP | disclosed |
| EP-0102740-A1 | N-formyl and n-hydroxymethyl-3-phenoxy-1-azetidinecarboxamides and their preparation and use | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-03-14 | — | — | EP | disclosed |
| EP-0102194-A1 | 3-Phenoxy-1-azetidinecarboxamides and their use and preparation | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | SLC6A4 502/4885SLC6A2 475/4885SLC6A3 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.